Shweta Maniar Buys Shares of RxSight, Inc. (RXST)
Shweta Maniar acquired 37,037 shares of RxSight, Inc. in a recent transaction.
Key Points
- Shweta Maniar purchased 37,037 shares of RxSight, Inc. on June 17, 2026, without a planned transaction code.
- RxSight, Inc. trades at $4.73 with a market cap of about $195.8 million and a forward P/E of -8.45.
- Institutions like BlackRock and Millennium Management adjusted their positions in RxSight, while analysts maintain varied price targets.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Shweta Maniar recently bought 37,037 shares of RxSight, Inc. (NasdaqGM: RXST) on June 17, 2026. This insider transaction was not part of a planned trading program, indicating a direct acquisition of shares by Maniar.
What Changed in Shweta Maniar's RxSight, Inc. Position
This move by Shweta Maniar marks a significant personal investment in RxSight, Inc. The transaction involved the purchase of 37,037 shares, although the specific financial value of the transaction wasn't disclosed.
Other Institutional Activity in RxSight, Inc.
Several institutional investors have also been active in RxSight, Inc. BlackRock, Inc. increased its holdings by 482,086 shares, ending with 3,187,092 shares valued at approximately $19.63 million. Meanwhile, Millennium Management LLC reduced its position by 69,579 shares, leaving it with 2,059,459 shares worth about $12.69 million. Artisan Partners Limited Partnership also cut its stake by 98,580 shares, holding 2,058,684 shares valued at $12.68 million. Nomura Holdings Inc. maintained its position at 2,000,060 shares, worth around $12.32 million. Additionally, D. E. Shaw & Co., Inc. added 75,903 shares to their portfolio, totaling 1,959,732 shares valued at $12.07 million.
RxSight, Inc. Stock Down 32.9%
Shares of RxSight, Inc. are trading around $4.73. The company has a market capitalization of roughly $195.8 million and a forward P/E ratio of -8.45, indicating it is not currently profitable. The stock has experienced a 52-week low of $4.48 and a high of $14.29. Its 50-day moving average stands at $6.09, while the 200-day moving average is $8.36. RxSight, Inc. has a current ratio of 10.2 and a quick ratio of 8.78, with a debt-to-equity ratio of 4.05.
$RXST stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
In its latest earnings report, RxSight, Inc. recorded revenue of $127.5 million, although it faced a revenue decline of 18.5%. The company posted a net margin of -36.6% and a return on equity of -17.1%. The next earnings announcement is expected on August 6, 2026.
Insider Buying and Selling at RxSight, Inc.
On June 17, 2026, several insiders at RxSight, Inc. made notable purchases. Shweta Maniar, along with Juliet Tammenoms Bakker, Robert Keith Warner, Robert Palmisano, William Link, and Jesse Anderson Corley, each acquired 37,037 shares. These transactions were not part of any pre-arranged trading plans.
Analysts Set New Price Targets
On May 7, 2026, Wells Fargo maintained a 'hold' rating with a $9.00 price target, while Needham maintained a 'buy' rating with an $11.00 target. Stifel also maintained a 'hold' rating with a $9.00 target on March 9, 2026. The consensus among analysts suggests an average target price of $8.79, based on seven opinions.
About RxSight, Inc.
RxSight, Inc. is a medical technology company based in Aliso Viejo, California. It specializes in the development and sale of light adjustable intraocular lenses used in cataract surgery. The company's innovative RxSight system allows for post-surgery vision adjustments, enhancing visual acuity for patients. Led by CEO Dr. Ronald M. Kurtz, RxSight employs 461 people and operates primarily in the healthcare sector, focusing on medical devices.
Bottom Line
Shweta Maniar's recent purchase of RxSight shares reflects a personal stake in the company amid varied institutional activities. While RxSight's stock has seen fluctuations, its innovative technology keeps it in focus. Investors should note that insider transactions can provide insights, but they are just one part of the broader market picture.
Get RxSight, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RXST, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.